A phase Ib trial, when lumretuzumab was added with pertuzumab and paclitaxel in 35 patients with HER3-positive HER2-low breast cancer, demonstrated a high incidence of diarrhea and a narrow therapeutic window [141]. The gene discussed is ERBB3; the disease is breast carcinoma.